The objectives of the study were to measure the pharmacokinetics and liver enhancement of gadoxetate (gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid [Gd-EOB-DTPA], Eovist, Primovist) after oral and intravenous administration in wild-type and (multidrug resistance–associated protein 2) Mrp2-deficient rats and to evaluate the in vitro transport of the contrast agent via intestinal and hepatic transporter proteins.
Gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid–enhanced magnetic resonance imaging and pharmacokinetics of Gd-EOB-DTPA after intravenous and oral administration were evaluated in wild-type and Mrp2-deficient rats using T1-weighted magnetic resonance imaging and a validated liquid chromatography–mass spectrometry method, respectively. Cellular uptake of Gd-EOB-DTPA was measured in stably transfected human embrionic kidney 293-cells expressing oragnic anion-transporting polypeptide 1A2 or organic cation transporter 3 and Madin Darby canine kidney 2-cells expressing apical sodium dependent bile acid transporter. The affinity to MRP2 and multidrug resistance–associated protein 3 was measured using inside-out vesicles.
In vitro, Gd-EOB-DTPA was demonstrated to be a substrate for OATP1A2 (mean [SD] of the Michaelis-Menten constant [K m], 1.0 [0.4] mmol/L; mean [SD] of the maximal uptake rate [V max], 101.3 [21.1] pmol/mg per minute), MRP2 (K m, 1.0 [0.5] mmol/L; V max, 86.8 [31.1] pmol/mg per minute), and multidrug resistance–associated protein 3 (K m, 1.8 [0.3] mmol/L; V max, 116 [15.9] pmol/mg per minute) but not for the apical sodium-dependent bile acid transporter and organic cation transporter 3. After the oral administration to the wild-type animals, Gd-EOB-DTPA was considerably absorbed from the small intestine (bioavailability, approximately 17%) and predominately eliminated via feces after intravenous dosing (approximately 96%). In the Mrp2-deficient rats, oral bioavailability increased to approximately 21% and Gd-EOB-DTPA was exclusively excreted into urine. Magnetic resonance enhancement of the liver was significantly prolonged in the Mrp2-deficient rats compared with the wild-type rats (mean [SD] area under the curve0-90, 36.4 [8.5] vs 14.8 [10.3] arbitary units per minute; P = 0.003; time to maximum plasma concentration, 48.6 [23.8] vs 6.0 [3.1] minutes; P = 0.001).
The nonmetabolized Gd-EOB-DTPA may have some potentials to be used as a probe-contrast agent to evaluate transporter-mediated mechanisms along the enterohepatic absorption route for drugs by functional visualization in vivo.
Supplemental Digital Content is available in the article.
From the *Department of Clinical Pharmacology, Center of Drug Absorption and Transport; †Department of Diagnostic Radiology and Neuroradiology, University Medicine of Greifswald; and Departments of ‡Pharmacology and §Pharmacy of the Center of Drug Absorption and Transport, University Medicine of Greifswald, Greifswald, Germany.
Received for publication May 24, 2013; and accepted for publication, after revision, July 26, 2013.
Conflicts of interest and sources of funding: Supported by the German Federal Ministry of Education and Research Grants InnoProfile 03IP612/03IP612X and Wachstumskern Centifluidic Technologies 03WKCC6C).
The authors report no conflicts of interest.
Supplemental digital contents are available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.investigativeradiology.com).
Reprints: Markus Keiser, DVM, Department of Clinical Pharmacology, Center of Drug Absorption and Transport, University Medicine Greifswald, Felix-Hausdorff-Str. 3, D-17487 Greifswald, Germany. E-mail: firstname.lastname@example.org.